Lv31
210 积分 2024-12-09 加入
Abstract 383: Trastuzumab deruxtecan resistance is associated with reduced responsiveness to topoisomerase inhibitors (payload resistance) but no reduction in sensitivity to HER2 tyrosine kinase inhibitors
1个月前
已关闭
BF‐BOIN‐ET: A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose Optimization
3个月前
已完结
LB011/#1557 Benmelstobart (TQB2450) alone or combined with anlotinib in previously treated advanced endometrial cancer: updated results from a multicohort, open-label, multicenter phase II clinical trial TQB2450-II-08
3个月前
已关闭
HER2 Targeted Agents in Gynecologic Cancers: An Updated Review
3个月前
已关闭
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
4个月前
已完结
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial
4个月前
已完结
Backfilling Patients in Phase I Dose-Escalation Trials Using Bayesian Optimal Interval Design (BOIN)
6个月前
已完结
The Lancet Breast Cancer Commission
7个月前
已完结
[Chinese expert consensus on the systemic treatment of advanced clear cell renal cell carcinoma (2024 edition)]
8个月前
已完结
[Quality control index for standardized diagnosis and treatment of renal cancer in China (2022 edition)]
8个月前
已完结
皖公网安备34019202002308
